chaperone

(redirected from Molecular chaperones)
Also found in: Dictionary, Thesaurus, Medical, Wikipedia.
See: protect
Mentioned in ?
References in periodicals archive ?
1 Prevents misfolding and promotes the refolding and proper assembly of unfolded polypeptides generated under stress conditions 2 Necessary for efficient RNA polymerase transcription elongation past template- encoded arresting sites 3 A molecular chaperone, thought to be involved in the initiation step of translation at high temperature.
Structure and function of the small heat shock protein/alpha-crystallin family of molecular chaperones.
LOS ANGELES -- CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company specializing in oncology, today announced that it has sold the worldwide rights to its molecular chaperone assets to privately-held, Copenhagen, Denmark-based Orphazyme ApS.
Washington, June 21 (ANI): Scientists have shown a molecular chaperone is working like a waste management company to collect and detoxify high levels of toxic amyloid beta peptide found in Alzheimer's disease.
LOS ANGELES -- CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical company, is permitted to re-enter the clinic with its orally administered molecular chaperone drug candidate arimoclomol as a therapeutic treatment for amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), following the U.
This extensive review of scientific data from multiple clinicians provides independent verification of the considerable potential of molecular chaperones in designing pharmaceuticals to treat a multitude of age-related diseases and disorders.
He is internationally recognized for his research on regulation of the heat shock stress response in animals and the function of molecular chaperones to repair protein damage that occurs in neurodegenerative diseases.
Focusing on the HSP90 family of molecular chaperones, the Company is developing drugs that induce destruction of specific signal transduction modulators critical for the growth of cancer cells.
In addition, under a sponsored research agreement, Conforma has initiated a research collaboration in the field of molecular chaperones with Duke Associate Professor of Cell Biology, Christopher Nicchitta, a leader in HSP90 biochemistry.
Because damaged proteins are thought to play a role in many diseases, regulation of molecular chaperones may have therapeutic efficacy in a broad range of disease states.
Because damaged proteins are thought to play a role in many diseases, CytRx believes that activation of molecular chaperones that help to reduce the accumulation of misfolded proteins may have therapeutic efficacy in a broad range of disease states.
We are looking for opportunities to capitalize on the value of our molecular chaperone assets to further support our oncology focus.

Full browser ?